ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
IMPALA Phase 3 Study of Molgradex Does Not Meet Primary Endpoint americanpharmaceuticalreview
June 14, 2019Savara announced top line data from IMPALA, a pivotal Phase 3 clinical study evaluating Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of aPAP ...
Pharma Sources Insight January 2025
